Parabilis Medicines: Overview, Contacts & Employment

About Parabilis Medicines

Industry

Biotechnology Research

Website

parabilismed.com

Headquarters

30 Acorn Park Dr, Cambridge, MA 02140, US

Company size

51-200

Founded

2016

Parabilis Medicines is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Cambridge, Massachusetts, dedicated to developing extraordinary medicines for people living with cancer. Operating within the biotechnology research industry, the company leverages its pioneering Helicon discovery platform to engineer precisely-tuned, stabilized helical peptide therapeutics capable of unlocking traditionally undruggable targets. Its lead clinical program, FOG-001, is a first-in-class TCF-blocking β-catenin inhibitor currently being evaluated in a Phase 1/2 study for colorectal cancer and other solid tumors, demonstrating the platform's ability to address undruggable intracellular protein-protein targets. Beyond this lead program, Parabilis is advancing a broader pipeline targeting proteins relevant to numerous cancers yet historically intractable with conventional drug modalities, exploring approaches such as protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. Well-capitalized with more than $500 million raised from leading life sciences investors, the company employs more than 190 people.